A Study to Determine the Effect of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Resistant (MBL-producing) Gram Negative Bacteria.
Phase 3
Recruiting
- Conditions
- Bacterial infection, unspecified, (2) ICD-10 Condition: K650||Generalized (acute) peritonitis, (3) ICD-10 Condition: J159||Unspecified bacterial pneumonia, (4) ICD-10 Condition: N390||Urinary tract infection, site notspecified,
- Registration Number
- CTRI/2019/06/019884
- Lead Sponsor
- Pfizer Limited
- Brief Summary
Phase 3 study to determine the efficacy, safety, and tolerability of aztreonam- avibactam (ATM- AVI) versus best available therapy (BAT) in the treatment of hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia (NP) including hospital acquired pneumonia (HAP) and ventilator associated pneumonia (VAP), complicated urinary tract infections (cUTI), or bloodstream infections (BSI) due to metallo-β-lactamase (MBL)- producing Gram-negative bacteria.
Due to the Character Limitation we could not capture the below few point in the Inclusion criteria. Hence, we are providing the same here:
2. Consecutive positive duplicate blood cultures (n=2) within 5 days prior to screening indicating presence of a carbapenem non- susceptible, MBL-producing Gram- negative bacteria. Subjects with polymicrobial blood infections may be included in the study.
3. Signs and symptoms of systemic infection characterised by at least one of the following:
a. Chills, rigors, or fever (temperature of ≥38.0°C or ≥100.4°F);
b. Elevated white blood cell count (≥10,000/mm3) or left shift (>15% immature polymorphonuclear leukocytes (PMNs)).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Inclusion Criteria All Subjects 1. Subject must be ≥18 years of age. 2. Evidence of a personally signed and dated informed consent document indicating that the subject or a legally acceptable representative has been informed of all pertinent aspects of the study. 3. Subjects must have a confirmed diagnosis of serious bacterial infection, specifically cIAI, HAP/VAP, cUTI, or BSI requiring administration of IV antibacterial therapy. 4. Subjects must have an MBL- positive Gram- negative bacteria (an Enterobacteriaceae and/or Stenotrophomonas maltophilia for which the imipenem or meropenem MIC is ≥ 4 μg/mL), that was isolated from an appropriate specimen obtained within 5 days prior to screening. 5. Female subject of childbearing potential must have a negative serum or urine pregnancy test, with sensitivity of at least 25 mIU/mL. 6. Subjects who have received appropriate prior systemic antibiotic[s] for a carbapenem nonsusceptible pathogen must meet the following criteria (Note: antibiotic[s] is considered appropriate if microbiological susceptibility test results show that all carbapenem non-susceptible pathogens are susceptible to the systemic antibiotic[s] received): 1. Worsening or lack of improvement of objective symptoms or signs of infection after at least 48 hours of antibacterial therapy Note: Symptomatic subjects (see inclusion criteria 3 and 4) with an isolated causative pathogen that was not susceptible to the prior systemic therapy are eligible for this trial. 7. Subject must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Additional Inclusion Criteria- cIAI Subjects 1. Subject must have a specimen obtained from an abdominal source during a surgical intervention within 5 days prior to screening from which a study qualifying pathogen was isolated upon culture. Surgical intervention includes open laparotomy, percutaneous drainage of an abscess, or laparoscopic surgery. 2. The subject has at least 1 of the following diagnosed during the surgical intervention: Cholecystitis with gangrenous rupture or perforation or progression of the infection beyond the gallbladder wall; Diverticular disease with perforation or abscess; Appendiceal perforation or peri-appendiceal abscess; Acute gastric or duodenal perforations, only if operated on >24 hours after diagnosis; Traumatic perforation of the intestines, only if operated on >12 hours after diagnosis; Other secondary peritonitis (not primary/ spontaneous bacterial peritonitis associated with cirrhosis or chronic ascites); Intra abdominal abscess (including of the liver and spleen provided that there is extension beyond the organ with evidence of intra peritoneal involvement). 3. Subject has at least 1 of the following signs / symptoms from each of the following 2 groups: Group A: Evidence of systemic inflammatory response: Documented fever (defined as body temperature ≥38°C) or hypothermia (with a rectal core body temperature ≤35°C); Elevated white blood cells (WBC) (>12000 cells/μL); Systolic blood pressure (SBP) <90 mmHg or mean arterial pressure (MAP) <70 mmHg, or a SBP decrease of >40 mmHg; Increased heart rate ( >90 beats per minute [bpm]) and respiratory rate (>20 breaths/min); Hypoxemia (defined as oxygen [O2] saturation <95% by pulse oximetry); Altered mental status. Group B: Physical findings consistent with intra abdominal infection, such as: Abdominal pain and/or tenderness, with or without rebound; Localized or diffuse abdominal wall rigidity; Abdominal mass. Additional Inclusion Criteria.
- HAP/VAP Subjects 1. Onset of symptoms >48 hours after admission or <7 days after discharge from an inpatient care facility (for which the duration of admission was >3 days). 2. New or worsening infiltrate on chest X- ray (or computerized tomography [CT]- scan) obtained within 48 hours prior to randomization. 3. At least 1 of the following: • Documented fever (temperature ≥38°C) or hypothermia (rectal/core temperature ≤35°C); • WBC ≥10,000 cells/mm3, leukopenia with total WBC ≤4500 cells/mm3, or >15% immature neutrophils (bands) noted on peripheral blood smear. 4. At least 2 of the following: • A new cough (or worsening of cough at Baseline); • Production of purulent sputum or purulent endotracheal secretions; • Auscultatory finding consistent with pneumonia/pulmonary consolidation (eg, rales, rhonchi, bronchial breath sounds, dullness on percussion, egophony); • Dyspnea, tachypnea, or hypoxemia (O2 saturation <90% or partial pressure of O2 [pO2]<60 mmHg while breathing room air); • Need for acute changes in the ventilator support status/system to enhance oxygenation, as determined by worsening oxygenation (arterial blood gas [ABG] or pO2 in arterial blood [PaO2]/fraction of inspired O2 [FiO2]) or needed changes in the amount of positive end expiratory pressure. 5. Subjects must have a respiratory specimen obtained within 5 days prior to screening for Gram stain and culture from which a study qualifying pathogen was isolated upon culture. This includes culture of either an expectorated sputum or a specimen of respiratory secretions obtained by endotracheal aspiration in intubated subjects, or by bronchoscopy with bronchoalveolar lavage (BAL), mini BAL or protected specimen brush (PSB) sampling. Additional Inclusion Criteria.
- cUTI Subjects 1. Subject had urine within 5 days prior to screening that cultured positive; containing ≥10 to the power of 5 colony forming unit (CFU)/mL of at least 1 carbapenem non susceptible, MBL positive Gram negative bacteria, ie, the isolate from the study qualifying culture. 2. Subject had pyuria in the 5 days prior to screening as determined by a midstream clean catch or catheterized urine specimen with ≥10 white blood cells (WBCs) per HighPower Field (HPF) on standard examination of urine sediment or ≥10 WBCs/mm3 in unspun urine. 3. Subject demonstrates either acute pyelonephritis or complicated lower UTI without pyelonephritis as defined by the following criteria: a. Acute pyelonephritis indicated by flank pain (which must have onset or worsened within 7 days of enrollment) or costovertebral angle tenderness on examination and at least 1 of the following: i) Fever, defined as body temperature ≥38°C (with or without patient symptoms of rigor, chills, or warmth); ii) Nausea and/or vomiting. OR b. Complicated lower UTI, as indicated by qualifying symptoms plus at least 1 complicating factor as follows: i) Qualifying symptoms: subject must have at least 2 of the following symptoms with at least 1 symptom from Group A: • Group A symptoms include dysuria, urgency, frequency, and or suprapubic pain; Group B symptoms include fever (defined as body temperature ≥38°C with or without patient symptoms of rigor, chills, warmth), nausea, and/or vomiting. ii) Complicating factors: subject must have at least 1 of the following complicating factors: • Documented history of urinary retention (male subjects); • Obstructive uropathy that is scheduled to be medically or surgically relieved during study therapy and before the EOT; Functional or anatomical abnormality of the urogenital tract, including anatomic malformations or neurogenic bladder, or with a postvoid residual urine volume of at least 100 mL; Use of intermittent bladder catheterization or presence of an indwelling bladder catheter for at least 48 hours; Urogenital procedure (such as cystoscopy or urogenital surgery) within the 7 days prior to obtainment of the specimen used for the study qualifying culture. Additional Inclusion Criteria.
- BSI Subjects 1. Subject has a confirmed diagnosis of primary BSI or catheter related BSI (CR- BSI).
Exclusion Criteria
- Exclusion Criteria All Subjects 1. Subject has an Acute Physiology and Chronic Health Evaluation (APACHE) II score >30. 2. Subjects unlikely to respond to up to 14 days of study treatment. 3. History of serious allergic reaction (anaphylaxis, angioedema, bronchospasm, hypersensitivity) to any systemic antibacterial allowed per protocol. 4. Subject has previously been treated with ATM-AVI Subject with known Clostridium difficile associated diarrhea. 5. Subjects with perinephric infection. 6. Colonization with an MBL-producing Gram-negative bacteria without signs or symptoms. 7. Estimated CrCL ≤15 mL/min or anticipated requirement for dialysis during the study. 8. Hepatic disease as indicated by ALT or AST >3 x ULN at Screening. Exception: AST and/or ALT up to 5 x ULN if these elevations are acute and directly related to the infectious process. 9. Bilirubin greater than 2 X ULN, unless related to the acute infection or due to known Gilberts disease. 10. Alkaline phosphatase (ALP) >3 x ULN. Exception: up to <5 x ULN if this value is acute and related to the infectious process. 11. Absolute neutrophil count <500/mm3. Additional Exclusion Criteria.
- cIAI Subjects 1. Subject has infections limited to the hollow viscous, such as simple cholecystitis, gangrenous cholecystitis without rupture, and simple appendicitis, or has acute suppurative cholangitis, infected necrotizing pancreatitis, or pancreatic abscess. 2. Subject has abdominal wall abscess or small bowel obstruction without perforation or ischemic bowel without perforation. 3. Subject has a cIAI managed by staged abdominal repair (STAR), or "open abdomen" technique, or marsupialization. This criterion is intended to exclude subjects in whom the abdomen is left open,particularly those for whom re operation is planned. 4. Subject who has prior liver, pancreas or small bowel transplant. Additional Exclusion Criteria.
- HAP/VAP Subjects 1. APACHE II score <10. 2. Subjects with lung abscess, pleural empyema, or post obstructive pneumonia. 3. Subject is a recipient of a lung or heart transplant. 4. Subjects with myasthenia gravis. Additional exclusion criteria.
- cUTI Subjects 1. Subjects with suspected or confirmed complete obstruction of any portion of the urinary tract, perinephric or intrarenal abscess, or prostatitis, or history of any illness that, in the opinion of the investigator, may confound the results of the study or pose additional risk in administering the study therapy to the subject. 2. Subjects with renal transplantation. 3. Subjects with a permanent urinary diversion (eg, with ileal loops, cutaneous ureterostomy or vesicoureteral reflux). 4. Subjects who are likely to receive ongoing antibacterial drug prophylaxis after treatment of cUTI (eg, subjects with vesico-ureteric reflux). 5. Any recent history of trauma to the pelvis or urinary tract. 6. Subjects with uncomplicated urinary tract infections (generally female subjects with urinary frequency, urgency, or pain or discomfort without systemic symptoms or signs of infection). Additional exclusion criteria.
- BSI Subjects 1. Subject has a prosthetic cardiac valve or synthetic endovascular graft. 2. Subject has a suspected or documented medical condition with well-defined requirement for prolonged antibiotic treatment (eg, infectious endocarditis, osteomyelitis /septic arthritis, undrainable /undrained abscess, unremoveable /unremoved prosthetic associated infection).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of subjects with clinical cure in the microbiological Intent-To-Treat (micro-ITT) analysis set Up to 31 days
- Secondary Outcome Measures
Name Time Method Proportion of subjects with clinical cure in the Microbiologically Evaluable (ME) analysis set up to 31 days Proportion of subjects with clinical cure in the micro-ITT and ME analysis sets within 24 hours after the completion of the last infusion of IV study treatment Proportion of subjects with a favorable per subject microbiological response in the micro ITT and ME analysis sets Proportion of subjects with a favorable per pathogen microbiological response in the micro ITT and ME analysis sets Time Frame: within 24 hours after the completion of the last infusion of IV Proportion of subjects who died on or before 28 days in the Intent-To-Treat (ITT) and micro-ITT analysis sets from randomization up to 31 days Incidence and severity of adverse events from first dose up to 48 days Incidence of abnormalities in physical examination from first dose up to 48 days Incidence of vital sign abnormalities from first dose up to 48 days Incidence of ECG abnormalities from first dose up to 48 days Incidence of clinical laboratory abnormalities from first dose up to 48 days
Trial Locations
- Locations (6)
Apollo Hospital
🇮🇳Chennai, TAMIL NADU, India
Artemis hospital
🇮🇳Gurgaon, HARYANA, India
Government Medical College
🇮🇳Kozhikode, KERALA, India
Lata Mangeshkar Medical Foundations Deenanath Mangeshkar Hospital and Research Centre
🇮🇳Pune, MAHARASHTRA, India
S R Kalla memorial gastro and General Hospital
🇮🇳Jaipur, RAJASTHAN, India
Victoria Hospital, Bangalore Medical College and Research Institute (BMCRI)
🇮🇳Bangalore, KARNATAKA, India
Apollo Hospital🇮🇳Chennai, TAMIL NADU, IndiaDr Ramasubramanian VenkatasubramanianPrincipal investigator919840078979idisdoc@gmail.com